Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent

• Published in: European journal of medicinal chemistry Vol. 267; p. 116205
• Main Authors: Yang, Haoyi, Zhang, Dongyu, Yuan, Ziyang, Qiao, Haishi, Xia, Zhuolu, Cao, Feng, Lu, Yuanyuan, Jiang, Feng
• Format: Journal Article
• Language: English
• Published: ISSY-LES-MOULINEAUX Elsevier Masson SAS 05.03.2024; Elsevier
• Subjects: 4-Aryl-4H-chromene; Animals; Anti-glioblastoma; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; BBB permeability; Benzopyrans - pharmacology; Benzopyrans - therapeutic use; Cell Line, Tumor; Cell Proliferation; Chemistry, Medicinal; Drug Screening Assays, Antitumor; Glioblastoma - drug therapy; Humans; Life Sciences & Biomedicine; Mice; Microtubule-targeting agent; Microtubules - metabolism; Molecular Docking Simulation; Pharmacology & Pharmacy; Science & Technology; Structure-Activity Relationship; Tubulin - metabolism; Tubulin Modulators - pharmacology; Anti-glioblastoma; 4-Aryl-4H-chromene; Microtubule-targeting agent; BBB permeability; DESIGN; DISCOVERY; STRATEGIES; MOLECULES; DISRUPTION; BIOLOGICAL EVALUATION; CHEMISTRY; INHIBITORS; TUBULIN; SCAFFOLD
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2024.116205

In this study, a series of novel 4-Aryl-4H-chromene derivatives (D1-D31) were designed and synthesized by integrating quinoline heterocycle to crolibulin template molecule based on the strategy of molecular hybridization. One of these compounds D19 displayed positive antiproliferative activity against U87 cancer cell line (IC50 = 0.90 ± 0.03 μM). Compound D19 was verified as the microtubule-targeting agent through downregulating tubulin related genes of U87 cells, destroying the cytoskeleton of tubulins and interacting with the colchicine-binding site to inhibit the polymerization of tubulins by transcriptome analysis, immune-fluorescence staining, microtubule dynamics and EBI competition assays as well as molecular docking simulations. Moreover, compound D19 induced G2/M phase arrest, resulted in cell apoptosis and inhibited the migration of U87 cells by flow cytometry analysis and wound healing assays. Significantly, compound D19 dose-dependently inhibited the tumor growth of orthotopic glioma xenografts model (GL261-Luc) and effectively prolonged the survival time of mice, which were extremely better than those of positive drug temozolomide (TMZ). Compound D19 exhibited potent in vivo antivascular activity as well as no observable toxicity. Furthermore, the results of in silico simulation studies and P-gp transwell assays verified the positive correlation between compound D19's Blood-Brain Barrier (BBB) permeability and its in vivo anti-GBM activity. Overall, compound D19 can be used as a promising anti-GBM lead compound for the treatment of glioblastoma. [Display omitted] •Thirty-one 4-Aryl-4H-chromene derivatives were synthesized and investigated.•The compound D19 acted as the microtubule-targeting agent.•The compound D19 displayed excellent anti-glioblastoma activity in vivo.